AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own ADT today, you need to believe in a steady, cash-generating security business that can keep converting its large installed base into recurring earnings, even if revenue growth stays moderate. The recent additions to the S&P 600, S&P 1000 and S&P Composite 1500 slot neatly into that story by broadening ADT’s audience: index trackers and benchmark-aware funds may now have to pay closer attention to a stock that already screens as inexpensive on earnings and cash flow metrics. In the short term, that can reinforce existing catalysts around buybacks and dividends, but it does not change the fundamental questions investors are still wrestling with: interest coverage, the sustainability of earnings growth and how the refreshed leadership team prioritizes capital allocation. Index inclusion amplifies the story; it does not rewrite it.
However, one key financial risk around ADT’s interest burden is easy to overlook. ADT's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 3 other fair value estimates on ADT - why the stock might be worth just $9.05!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com